First and foremost, it was no surprise that the company was going to need to raise funds. It’s important to keep in mind that the company recently released positive results from a Phase 3 clinical study of Voclosporin in Lupus Nephritis.
The study showed that the drug is far superior to the standard of care, giving it a strong chance of approval. As such, AUPH needed to do one of two things. It would either have to find a partner to help foot the bill associated with commercialization, and share in the profits, or find a way to fund commercialization itself.
With this news, we now know that AUPH has the funding that it needs in order to move forward with the successful launch of Voclosporin, should the drug be approved. Considering its high level of efficacy, the drug could quickly become the standard of care in the multi-billion dollar Lupus Nephritis market.
Considering this, a little dilution for the greater good isn’t necessarily a bad thing. Knowing that the company has the funding it needs to move forward with commercialization once the drug is approved outweighs any concerns associated with dilution, leading to strong gains.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!